|
Mutation Information
|
Mutation Site
|
T109I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
C |
|
Relevant Drug
|
ABI-H0731 |
Literature Information
|
PubMed PMID
|
32868329
|
|
Published Year
|
2020 |
|
Journal
|
Antimicrobial agents and chemotherapy |
|
Title
|
Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. |
|
Author
|
Huang Q,Cai D,Yan R,Li L,Zong Y,Guo L,Mercier A,Zhou Y,Tang A,Henne K,Colonno R |
|
Evidence
|
ABI-H0731 exhibited the greatest loss of potency against the T109I and T109M variants, with a loss of antiviral activity of >68-fold.
|
|
|
HBV Mutation Detail Information